Raptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference  

NOVATO, Calif., June 07, 2016 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced it will be participating in the 39th European Cystic Fibrosis Society (ECFS) conference and will present data from clinical studies conducted with QUINSAIR™, an inhaled formulation of levofloxacin, a fluoroquinolone antibiotic. The meeting will take place in Basel, Switzerland at the Congress Center Basel from Wednesday, June 8 to Saturday, June 11, 2016.

Two posters for QUINSAIRTM will be presented at ECFS on Friday June 10 from 2:00 p.m. – 3:00 p.m. (times are CEST) on Level 1, Hall 4.1 in Poster Area A:

  • Microbiologic Changes Observed over 6 months in a Randomized, Open-Label Comparison of Inhaled Levofloxacin and Inhaled Tobramycin in Persons with CF and Chronic P. aeruginosa (Pa) Airway Infection, D.R. VanDevanter – Poster number 37.
  • History of Pulmonary Exacerbations (PEx) as a Predictor of Response to Nebulized Levofloxacin Compared with Nebulized Tobramycin, P.A. Flume – Poster number 38.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. Raptor is leading the global commercialization of two products for orphan diseases, including PROCYSBI®, for the management of nephropathic cystinosis in adults and children ages two years and older, and QUINSAIRTM, an inhaled fluoroquinolone antibiotic for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). Raptor’s R&D pipeline includes RP103, known commercially as PROCYSBI®, for Huntington’s disease and mitochondrial disorders, including Leigh syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU. The pipeline also includes MP-376, known commercially as QUINSAIRTM, which has Qualified Infectious Disease Product (QIDP) designation for three distinct indications: the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa, in patients with CF and in patients with non-cystic fibrosis bronchiectasis (BE), and in patients with nontuberculous mycobacteria (NTM). Raptor holds orphan drug designation in the U.S. for MP-376 for the treatment of CF, which, when added to the five years of exclusivity associated with QIDP designation, would confer 12 years of regulatory exclusivity upon FDA approval. For additional information, please visit www.raptorpharma.com.

Kimberly Lee, D.O.
Vice President, Corporate Strategy and Communications
Raptor Pharmaceutical Corp.
(415) 408-6351

Robert H. Uhl
Westwicke Partners, LLC
Managing Director
(858) 356-5932

Monica May
Canale Communications
(619) 849-5383